|
 |
|
|
| |
News - April, 2008
The Rocky Mountain Blood and
Marrow Transplant Program is committed to ongoing
education in the field. We are providing the latest
treatment and research news around our program for
patients and their caregivers and physicians.
|
04-30-2008 |
Molecular change may reveal risk of leukemia relapse
Researchers may have discovered a better way to distinguish acute leukemia patients who require aggressive treatment to prevent recurrence from those who need only standard therapy for cure.
|
|
04-24-2008 |
New lymphoma therapies targets diverse and difficult cancer
The fifth leading cause of cancer in the United States, lymphoma is made up of more than 40 rare and highly diverse diseases that target the body's lymphatic system. Lymphomas include both one of the fastest growing cancers -- Burkitt's lymphoma, which can double in size in as little as a day -- and one of the slowest, chronic lymphocytic leukemia (CLL).
|
|
04-22-2008 |
Risk Of Second Cancers Greatest In Younger Patients Treated For Non-Hodgkins Lymphoma (external link)
For survivors of non-Hodgkin's lymphoma the risk of developing subsequent secondary cancers is greater the younger the patient's age at diagnosis, concludes a study published in the Journal of Clinical Oncology. The study also showed that the toll of subsequent solid tumours was largest 21 to 30 years after diagnosis.
|
|
04-18-2008 |
ZIOPHARM Presents Positive Data From Phase II Study Of Darinaparsin In Advanced Hematological Malignancies At AACR 2008 Annual Meeting
ZIOPHARM Oncology, Inc. announced that it presented positive data from a phase II study of darinaparsin, the Company's novel organic arsenic compound, in advanced hematological malignancies at the American Association for Cancer Research (AACR) Annual Meeting, in San Diego, CA.
|
|
04-16-2008 |
Experimental Drug Shows Promise in Treating One Class of Lymphoma
New clinical data showed some cancer patients with recurrent lymphoma benefited from an experimental drug called AME-133v, said a researcher at the University of Alabama at Birmingham (UAB).
|
|
04-14-2008 |
Immunomedics Reports Veltuzumab Enhances Radioimmunotherapy With Epratuzumab in Lymphoma Model
Immunomedics, a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported that combining veltuzumab, the Company's proprietary humanized anti-CD20 antibody, with yttrium-90-labeled epratuzumab, its humanized anti-CD22 antibody, improves treatment responses in a human lymphoma model. The preclinical results were presented at the 2008 Annual Meeting of American Association for Cancer Research in San Diego, California.
|
|
04-14-2008 |
St. Jude discovery offers new avenues to understanding an aggressive form of leukemia
Researchers at St. Jude Children¡¦s Research Hospital have discovered evidence that a series of genetic mutations work together to initiate most cases of an aggressive and often-fatal form of acute lymphoblastic leukemia (ALL).
|
|
04-09-2008 |
Statins May Reduce Effectiveness of Rituxan® in Non-Hodgkin’s Lymphoma (external link)
Researchers from Poland have reported that statins may reduce the effectiveness of Rituxan® (rituximab) in treatment of non-Hodgkin’s lymphoma (NHL). The details of this study were published online in PLoS Med (the Public Library of Science journal) on March 25, 2008.
|
|
04-08-2008 |
Seattle Genetics Announces Initiation of Phase Ib Clinical Trial of SGN-40 in Combination with Rituxan and Gemzar for Non-Hodgkin Lymphoma
Seattle Genetics, Inc. announced today that it has initiated a phase Ib clinical trial of SGN-40 in combination with Rituxan(R) (rituximab) and Gemzar(R) (gemcitabine) for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma.
|
|
04-07-2008 |
Med BioGene Confirms High Accuracy Rate for LymphExpress Dx
Med BioGene Inc. (TSX VENTURE:MBI), a life science company focused on the development and commercialization of genomic-based diagnostic tests for cancer and cardiovascular disease, today announced results from a recent study that confirm the previously demonstrated high accuracy rate of LymphExpress DxTM v.1.0.
|
|
04-06-2008 |
Increased Life Expectancy Seen For Patients With Advanced Colorectal, Ovarian and Testicular Cancer (external link)
A new study indicates that patients receiving treatments for late stage testicular, colorectal and ovarian cancer have increased life expectancy, resulting from the proportion of patients cured or by prolonging survival among non-cured patients. The research reveals that mathematical models and population level data can be used to determine how treatment advances are changing survival and are impacting mortality. The study is published in the May 15, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
|
|
04-01-2008 |
Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that it has initiated a Phase 1/2 clinical trial of TRU-016, the company's lead proprietary Small Modular ImmunoPharmaceutical (SMIP(TM)) drug candidate, for the treatment of chronic lymphocytic leukemia (CLL). The company also announced a new, next-generation product candidate for clinical evaluation and provided an update on its product pipeline.
|
|
|
|
|
|
|
